Regulation of influenza a virus mRNA splicing by CLK1 by Artarini, A. et al.
1. Supplementary Methods 
1.1. siRNA transfection in A549 cells. All siRNAs were purchased from Qiagen and the 
sequences are provided in Supplementary Table 1. For siRNA transfection in 12-well plates, 1 
µl of 20 µM siRNA stock was diluted in 99 µl RPMI (Gibco) supplemented with 25 mM Hepes 
(Gibco) and incubated at room temperature for 5 minutes, then 4 µl Hiperfect (Qiagen) was 
added and incubated for 25 minutes at room temperature. This solution was then added to 
900 µl A549 cell suspension containing 5x104cells and incubated at 37 oC and 5% CO2. At 24 
hours post siRNA transfection, culture medium was replaced and cells incubated at 37 oC and 
5% CO2 for another 24 hours. For transfection in 384-well plates, 4 µl of 200 nM siRNA per 
well was mixed with 8 µl RPMI supplemented with 25 mM HEPES containing 0.35 µl Hiperfect 
and incubated at room temperature for 10 minutes. A suspension of 2000 A549 cells in 30 µl 
medium was then added to the siRNA-lipid mixture in each well and incubated at 37oC with 
5% CO2 for 48 hours.  
1.2. Virus infection. Influenza virus stock was diluted in cold infection buffer (PBS 
supplemented with 0.2% bovine serum albumin, 100 mM CaCl2 and 100 mM MgCl2) according 
to the specified multiplicity of infection (MOI). Cells used for infection were washed with 1x 
PBS, then virus solution was added to the cells and incubated at room temperature for 1 hour. 
Virus solution was then replaced with infection medium (DMEM supplemented with 0.2% 
bovine serum albumin, 4 mM L-glutamine and 100 U/ml penicillin/streptomycin) and cells 
incubated at 37 oC, 5% CO2 for the specified infection time. For influenza virus replication 
assay, A549 cells were infected at MOI 0.01 with infection medium supplemented with 10 
µg/ml TPCK-treated trypsin (Sigma). At the specified time post-infection, the medium was 
collected and titer of virus progeny in the supernatant was quantified by infection of MDCK 
cells for 6 hours followed by indirect immunofluorescence staining.  
1.3. Indirect immunofluorescence staining for virus titer determination. Cells were fixed with 
3.7% formaldehyde overnight at 4oC, washed twice with PBS and blocked with PBS/0.3% Triton 
X-100/10% FCS for 10 minutes at room temperature. Antibody against viral nucleoprotein (NP, 
clone AA5H, AbD Serotec), diluted at 1:10,000 in PBS/10% FCS/0.1% Tween 20, was then 
added to cells and incubated at room temperature for 1 hour. Cells were washed once with 
PBS/0.1% Tween 20 for 5 minutes, followed by incubation with secondary Cy3-labelled anti-
mouse IgG (1:100, Jackson Immuno Research Lab) containing 10 µg/ml Hoechst (Sigma) in 
PBS/10% FCS/0.1% Tween 20 for 1 hour at room temperature. Cells were washed 3 x with PBS 
+ 0.1% Tween 20 and kept in PBS. Fluorescence images were acquired and analyzed using the 
ScanR software (Olympus) as described previously (Karlas et al., 2010). The normalization was 
performed by dividing the infection rate (%) of the inhibitor by the average of infection rate 
(%) from all DMSO controls. The infection rate was obtained from the immunofluorescence 
data of MDCK cells infected with the supernatant of A549 cells treated with inhibitor and 
infected with A/WSN/H1N1 virus. The final virus titer can be extrapolated from the infection 
rate based on the following formula: multiplicity of infection = -ln(1- infection rate) as 
described recently (Lesch et al., 2019). 
1.4. Isolation of primary cells from murine lungs. Whole lungs of mice with equal weights 
were removed under sterile conditions from sacrificed mice and kept in DMEM-F12 
supplemented with penicillin-streptomycin. The lungs were washed in PBS supplemented with 
antibiotics and cleaned from any fat tissue, then cut into small pieces and incubated in solution 
containing 1mg/ml Collagenase I and 2.5mg/ml dispase II (Sigma) at 37oC for 2 hours with 
constant stirring. Cells were then separated from the tissue by passing through a cell strainer 
and collected by centrifuging at 1200 rpm, 4°C for 5 min. Cells were washed once with PBS 
and resuspended in Quantum 286 (PAA) medium supplemented with antibiotics. Cells were 
cultured in Matrigel™-coated plates at 37°C with 5% CO2. Plates were prepared by adding a 
solution of 20 µl Matrigel™/ml cold PBS, followed by polymerization at 37oC for 2 hours. The 
solution was then removed and the plate was dried. 24 hours after cell preparation cells were 
washed with PBS supplemented with antibiotics to remove erythrocytes and fresh culture 
medium added. After incubation at 37oC with 5% CO2 for 4-5 days, cells were detached using 
Accutase (Sigma) at 37 oC for 10-15 min and resuspended in Quantum 286 medium 
supplemented with antibiotics and seeded in 24-well plates at 4x104 cells/well for influenza 
virus infection. 
1.5. Host cell viability determination by WST-1 assay. Determination of host cell viability 
upon siRNA transfection was performed using cell proliferation assay WST-1 (Roche). WST-1 
reagent was added to the cells 48 h after siRNA transfection or chemical inhibitor treatment 
and incubated at 37 oC for 1.5 h. Absorbance was measured at 460nm and at the reference 
wavelength 590 nm. Non-targeting siRNA Allstars or non-treated cells and siPLK1 (known to 
induce cytotoxicity due to knockdown of the endogenous gene polo-like kinase 1 (PLK1) were 
used as a positive and negative control, respectively. 
1.6. RNA analyses. Cells were lysed using Trizol (Invitrogen) and RNA was isolated according 
to manufacturer's instruction. For quantification of influenza M and NS mRNA, reverse 
transcription of total RNA was performed using Oligo-dT(18) primer and SuperScript III 
Reverse Transcription Kit (Invitrogen). cDNA was then subjected to quantitative PCR using 
Power SYBR® Green mix (Applied Biosystems) and primer pairs specific for M1 (5’-
GACCAATCCTGTCACCTC-3’ and 5’-GATCTCCGTTCCCATTAAGAG-3’), M2 (5’-
GAGGTCGAAACGCCTAT-3’ and 5’-CTCCAGCTCTATGTTGACAAA-3’) (Cheung et al., 2005), NS1 
(5’-TGACCGGCTGGAGACTCTAA-3’ and 5’-TGTCTCACTTCTTCAATCAACCA-3’), NS2 (5’-
GTGTCAAGCTTTCAGGACATAC-3’ and 5’-TGTCTCACTTCTTCAATCAACCA-3’)  and GAPDH (5’-
GGTATCGTGGAAGGACTCATGAC-3’ and 5’-ATGCCAGTGAGCTTCCCGTTCAG-3’). The relative 
mRNA level was calculated using the ΔΔCt method normalized to control treated cells with 
GAPDH as internal standard.  
Validation of RNAi experiment by quantitative PCR was performed as previously described 
(Machuy et al., 2005). Total RNA was isolated at 48 hours post siRNA transfection and relative 
mRNA level was quantified using qRT-PCR using Power SYBR® Green One-Step Kit (Applied 
Biosystems) and gene-specific primer as listed in Supplementary Table 2. The relative mRNA 
level was normalized to control transfected cells with GAPDH as internal standard. 
1.7. Western blotting. Protein samples were collected from A549 cells using 1xSDS sample 
buffer (75 mM Tris HCl (pH 6.8), 25% glycerol, 0.6% SDS, 7.5% β-mercaptoethanol and 
0.001% bromophenol blue) followed by incubation at 95oC for 10 minutes. Samples were 
then separated in 10-12% SDS-polyacrylamide gel and transferred to a PVDF membrane. The 
membrane was then blocked for 1 hour in Tris-buffered saline containing 3% bovine serum 
albumin and 0.1% Tween 20. Viral proteins were detected using antibodies against viral 
matrix protein (M1, 1:100, AbD Serotec), viral ion-channel protein (M2, 1:1000, Santa Cruz) 
or viral non-structural protein 1 (NS1, 1:1000, Santa Cruz). As loading control, antibody 
against cellular β-actin (1:2500, Sigma) was used. Membranes were developed with ECL 
western blotting detection reagent (Amersham).   
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2. Supplementary Figure Legends 
Figure S1 
Characterization of used siRNAs used in this study. (A) Viability of A549 cells transfected with 
the indicated siRNAs determined by WST-1 assay. Unlike PLK1, knockdown of CLK, SRPK or 
DYRK isoforms did not reduce cell viability significantly; calculated by one-way ANOVA with 
Dunnett´s post hoc test. (B) Knockdown levels on RNA level of indicated target genes in A549 
cells upon siRNA transfection. (C) Expression profile of murine CLK1 expression in lung cells 
isolated of the indicated mouse strains.    
Figure S2 
Influence of indicated chemical compounds on cell viability. A549 cells were cultivated in the 
presence of compounds at indicated concentrations for 48 h, and the viability was determined 
by WST-1 assay.   
Figure S3 
The influence of the CLK1 inhibitors on the splicing of the M and NS gene segment of influenza 
viruses (A/WSN/33) on mRNA and protein levels. (A-D) A549 cells were pre-treated with 
inhibitors for 2 h, then infected with influenza A/WSN/33 at MOI 4 for 5 h. The levels of M1, 
M2, NS1 and NS2 were determined by quantitative RT-PCR. (E-F) Quantification of M1, M2 
and NS1 protein level from immunoblots using ImageJ. The relative intensities were 
normalized to the loading control β-actin.  
Figure S4 
Characterization of siRNAs targeting SR proteins used in this study. (A) Viability of A549 cells 
transfected with the indicated siRNAs determined by WST-1 assay. (B) Knockdown levels on 
RNA level of indicated target genes in A549 cells upon siRNA transfection. Gene expression 
was determined by quantitative RT-PCR. (C) Knockdown levels of siRNA targeting SRSF3. A549 
cells were transfected with siRNA targeting SRSF3 or Allstars control in 12-well plate. The 
levels of SRSF3 were determined by quantitative RT-PCR. (D, E) Influence of the knockdown of 
SRSF3 on the splicing of the M and NS gene segment. A549 cells were transfected with siRNA 
targeting SRSF3 or Allstars control in 12-well plates. After 48 h, cells were infected with 
influenza A/WSN/33 at MOI 4 for 5 h. The levels of M1, M2, NS1 and NS2 were determined by 
quantitative RT-PCR. (F) Quantification of M1, M2 and NS1 protein level from immunoblots 
using ImageJ. The relative intensities were normalized to the loading control β-actin. 
Figure S5 
Structures of CLK inhibitors used in this study: KH-CB19, NIH-39, VCC080174, VCC463764. 
Figure S6 
Quantification of GFP positive cells with speckled and non-speckled pattern of SC35 staining.  
Figure S7 
Prediction of SRSF1, SRSF2, SRSF5, SRSF6 binding sites using ESE Finder 
(http://krainer01.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home) and  SRSF1 and 
SRSF3 binding sites using SFMap (http://sfmap.technion.ac.il/) using influenza A/WSN/33 M 
and NS mRNA sequences. Depicted binding sites were chosen for these SR proteins and the 
sites with highest prediction score. Data input sequences: Influenza A virus 
(A/WSN/1933(H1N1)) segment 7 matrix protein 2 (M2) and matrix protein 1 (M1) genes, 
complete cds (https://www.ncbi.nlm.nih.gov/nuccore/mf039638) and influenza A virus 
(A/WSN/1933(H1N1)) segment 8, complete sequence 
(https://www.ncbi.nlm.nih.gov/nuccore/cy034136). 
 
Table S1 
List of siRNA target sequences used  
Table S2 
List of primer sequences used 
Table S3 
List of compounds found to be effective against CLK1 by enzymatic screening. Shown are 
IC50 values determined by the Kinase-Glo Luminescent Kinase and the Caliper mobility shift 
assay. 
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Supplementary Table 1 
 
Target gene siRNA siRNA target sequence  
Clk1 
si1/ siClk1 CACGATAGTAAGGAGCATTTA 
si2 AACGTGATGAACGCACCTTAA 
Clk2 
si1 GTGAAATAGTGTAAATATGAA 
si2 TCGCCTGGATTGGGATGAGAA 
Clk3 
si1 CTGGTTCAACTTCCACGGTCA 
si2 CACGAAGATCTCGGTCCAGAA 
Clk4 
si1 CATAATTAACTTGTTAAGCAA 
si2 TACGTAAACCTATAAGAATTA 
SRPK1 
si1 ACGCTTATGGAACGTGATACA 
si2 CAGGAATTCTGGTGATATTAA 
SRPK2 
si1 CAGAAAGTGATTACACATATA 
si2 AAGGGTTAGATTACTTACACA 
DYRK1A 
si1 CTCTTTGAACCTAACACGAAA 
si2 CCTGCTCATATTCTTGACCAA 
SRSF1 
si1 TTGGCAGGATTTAAAGGATCA 
si2 CATCATAGTGCTTGCGTTTAA 
SRSF2 
si1 CTGCGGTCTCCTGTTTGATAA 
si2 CCGGGCCGCCACTCAGAGCTA 
SRSF3 
si1/siSRSF3 CAGACTGATAATAAACCTCTA 
si2 AACCCTAGATCTCGAAATGCA 
SRSF4 
si1 CAGGTCGAGATCCAATTCCAA 
si2 CAGAATCACGCTCCAGATCAA 
SRSF5 
si1 CAGAATTAGTTTAATGCCTTA 
si2 TTGCCTCTTATGGTGACTTAA 
SRSF6 
si1 GAGCATAGGGTTGACTGATAA 
si2 TAGCCACGACCAATTTATTAA 
SRSF7 
si1 CTGGATGATCTTTATACTAAT 
si2 CCCGACGTCCCTTTGATCCAA 
SRSF9 
si1 CAGGGCCATATTAGCAGTGAA 
si2 AGGATTTAGTGTCTTAGGAAA 
SRSF10 
si1 CGGGACTACTATAGCAGATCA 
si2 AACCGGGTGCTTCAAAGTACA 
SRSF11 
si1 AGGGAACTGGTGATTCACTAA 
si2 TTCGTTGACAGAGCTTTGATA 
PLK1 siPLK1 CCGGATCAAGAAGAATGAATA 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Table 2 
 
Target gene Primer Sequence (5’ – 3’) 
Clk1  
Forward TAGGGTGGTCCCAACCATGT 
Reverse AGGTCCAAGAATCCTTTCCATCA 
GAPDH 
Forward GGTATCGTGGAAGGACTCATGAC 
Reverse ATGCCAGTGAGCTTCCCGTTCAG 
Clk1 (mouse) 
Forward ACTGTGAAGCTGCTCAATCGGAAA 
Reverse ACCTCGATGCTCAAACCACTCCA 
GAPDH (mouse) 
Forward TCACCATCTTCCAGGAGCG 
Reverse AAGCAGTTGGTGGTGCAGG 
Clk2 
Forward TCGCCGCCAGAACGATGCCG 
Reverse CGCCGGTCATACACCCTCCGGT 
Clk3 
Forward GGACCTTCACGTTCTCGTCAT 
Reverse CGCTGCTACAAGACCTGGTG 
Clk4 
Forward GAGAACAGGCATTGTAAACCACA 
Reverse CCGATAATCTCGCTCATTCAAGG 
SRPK1 
Forward CCATGTGATCCGAAAGTTAGGC 
Reverse AGGGTCTGAATTGCGAACTGA 
SRPK2 
Forward CCGCGTCGGAATGAGCTCCC 
Reverse TGAGGCTCCGGCTTTTTCGGA 
DYRK1A 
Forward AAGAAGCGAAGACACCAACAG 
Reverse TTTCGTAACGATCCATCCACTTT 
SRSF1 
Forward CTCCAAGTGGAAGTTGGCAGGATT 
Reverse ACACCAGTGCCATCTCGGTAAACA 
SRSF2 
Forward TCGCTACAGCCGCTCGAAG 
Reverse ACTCTTCGATCGCGACCTG 
SRSF3 
Forward ACTTCATAAGCTTGGTGCAT 
Reverse ACACCTTTGTGTCACTGTTT 
SRSF4 
Forward TTAAGGGCTACGGGAAGATCC 
Reverse ATGCTCAACAATTACTCGCTCA 
SRSF5 
Forward GATTCTTCAAGGGATATGGACGG 
Reverse GACCGAGCCCTAGCATGTTC 
SRSF6 
Forward GGTACGGCTTCGTGGAGTTC 
Reverse GGGCGTGCTCTACGATCAC 
SRSF7 
Forward CGGTACGGAGGAGAAACCAAG 
Reverse AGCCACAAATCACCTTTCCATC 
SRSF9 
Forward GCTTCGTGTGGAGTTCCCC 
Reverse TCTTCTTGTAGGAGGCCCATT 
SRSF10 
Forward CAGAACTACGGCGAGCGGGAAT 
Reverse CGCCTGGAATCTTCCTTGGAGCG 
SRSF11 
Forward ATGAGCAACACTACCGTCGTC 
Reverse GGGAGACATTAGTCACCTGGAT 
 
 
 
Supplementary Table 3 
ID Clk1_Luciferase_IC50 (µM) Clk1_IC50 Labchip (µM) 
KH-CB19T N/A < 0.05 
VCC185059 0.027 0.187 
VCC463764 0.206 0.025 
VCC005651 0.035 0.021 
VCC080174 0.062 0.936 
VCC889564 0.063 0.381 
VCC460649 0.154 0.059 
VCC240536 0.114 0.347 
VCC424351 0.107 0.690 
VCC090131 0.005 0.000 
VCC316310 0.837 0.018 
VCC323745 0.039 0.050 
VCC352333 0.017 0.047 
VCC275426 0.276 0.911 
VCC209800 0.160 0.105 
VCC783456 0.301 0.078 
VCC440300 0.078 0.041 
VCC237658 0.018 0.626 
VCC322466 0.131 0.161 
VCC581887 0.032 0.245 
VCC185767 0.406 0.119 
VCC599621 0.054 0.032 
VCC000902 0.043 0.682 
VCC027029 0.406 0.033 
VCC084109 0.017 0.751 
VCC116601 0.020 0.022 
VCC230913 0.032 0.311 
VCC303142 0.005 0.037 
VCC348917 0.021 0.026 
VCC369679 0.042 0.019 
VCC386531 0.003 0.577 
VCC448924 0.005 0.016 
VCC497245 0.065 0.838 
VCC558180 0.012 0.114 
VCC815262 0.405 0.300 
VCC885878 0.565 0.011 
VCC892742 0.239 0.676 
VCC976022 0.176 0.014 
VCC372525 0.004 0.744 
VCC077038 0.034 0.017 
VCC936586 0.027 0.052 
VCC180519 0.046 0.014 
VCC140861 0.016 0.285 
VCC133766 0.023 0.096 
VCC445786 0.025 0.013 
VCC609838 0.084 0.055 
VCC754620 0.017 0.110 
VCC092207 0.201 0.073 
VCC283994 0.157 0.016 
VCC716806 0.364 0.136 
VCC378503 0.040 0.026 
VCC842416 0.255 0.201 
VCC303508 0.065 0.070 
VCC229760 0.022 0.021 
VCC657622 0.009 0.016 
VCC890061 0.020 0.217 
VCC762355 0.044 0.214 
 
